Zobrazeno 1 - 10
of 70
pro vyhledávání: '"YUKO KANBAYASHI"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract This study was conducted to examine times to onset, incidence rates, and outcomes of nivolumab-induced lung adverse events (AEs), using the Japanese Adverse Drug Event Report database. We analysed data for the period between April 2004 and M
Externí odkaz:
https://doaj.org/article/dc3ba449d39c47a0a99fbc6a99beb838
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract This study was undertaken to determine the risk of bevacizumab-induced lung toxicity, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. We analysed data for the period between April 2004 and March 20
Externí odkaz:
https://doaj.org/article/b6cc1acd00bd40aa8c8ec192fe597f5a
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and
Externí odkaz:
https://doaj.org/article/7e65446849354672bb53b9a0f067b4e2
Autor:
Yuko Kanbayashi, Koichi Sakaguchi, Fumiya Hongo, Takeshi Ishikawa, Yusuke Tabuchi, Osamu Ukimura, Koichi Takayama, Tetsuya Taguchi
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Abstract This retrospective study was undertaken to identify predictors for the development of hypocalcaemia even with prophylactic administration of calcium and vitamin D, and to help guide future strategies to improve the safety, efficacy, and QOL
Externí odkaz:
https://doaj.org/article/353aa48f9c784dce86d75c58824434a0
Autor:
Yuko Kanbayashi, Mayumi Shimizu, Yuichi Ishizuka, Shohei Sawa, Katsushige Yabe, Mayako Uchida
Publikováno v:
PLoS ONE, Vol 17, Iss 12, p e0278823 (2022)
BackgroundOpioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC
Externí odkaz:
https://doaj.org/article/0e2c5f5fc96c46ea914212ace43721a2
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0275481 (2022)
BackgroundOxaliplatin causes acute cold-induced neurotoxicity and chronic cumulative neuropathy, which can require dose modification and impacts quality of life. However, effective strategies for managing oxaliplatin-induced peripheral neuropathy (OI
Externí odkaz:
https://doaj.org/article/c1b4874fea224ad6bcb81f9bfc2cdd31
Autor:
Yuko Kanbayashi, Koichi Sakaguchi, Takeshi Ishikawa, Yoshimi Ouchi, Katsuhiko Nakatsukasa, Yusuke Tabuchi, Fuminao Kanehisa, Minako Hiramatsu, Ryo Takagi, Isao Yokota, Norito Katoh, Tetsuya Taguchi
Publikováno v:
Breast, Vol 49, Iss , Pp 219-224 (2020)
Background: Recently, the efficacy of cryotherapy and compression therapy to prevent taxane-induced peripheral neuropathy has been reported. We prospectively compared the efficacy of cryotherapy using a frozen glove (FG) and compression therapy using
Externí odkaz:
https://doaj.org/article/bcb98b82bf02465799b33003093ece82
Publikováno v:
Pain Research and Management, Vol 19, Iss 6, Pp e164-e167 (2014)
BACKGROUND:Pregabalin administration is occasionally abandoned due to adverse events such as somnolence, dizziness, unsteadiness, weight gain and edema. However, the exact causes of these differences in adverse events associated with pregabalin have
Externí odkaz:
https://doaj.org/article/1df3c24e322f44b99501a5b47d46ef24
Publikováno v:
Oncology.
Introduction: This retrospective study was conducted to identify risk factors for developing hand-foot syndrome (HFS) and to determine new strategies for improving quality of life (QoL) in patients undergoing chemotherapy. Methods: Between April 2014
Publikováno v:
Oncology.
Introduction: The efficacy of ponatinib was demonstrated in patients resistant or intolerant to prior BCR-ABL tyrosine kinase inhibitors. However, cardiac adverse events (CAEs) have become a concern as a serious side effect of ponatinib administratio